Compare Ascendis Pharma A/S (ASND) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Ryanair Holdings plc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Ryanair Holdings plc trades at $64.3 (market cap $31.76B). The key difference: Ryanair Holdings plc is the larger of the two by market cap, and Ryanair Holdings plc pays a 1.53% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | RYAAY | |
|---|---|---|
Market Cap | $17.74B | $31.76B |
Sector | Health | Industrials |
52-Week High | $277.18 | $73.82 |
52-Week Low | $163.32 | $53.24 |
Enterprise Value | $18.11B | $29.42B |
Dividend Yield | — | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
RYAAY trades at $64.65, up 0.78% today, with a bullish technical signal and strong fundamentals including a 13.9 P/E ratio and 25.37% ROE. Recent earnings beat expectations in three of the last four quarters, and June 2026 traffic grew 7% year-over-year. The company maintains a debt-free balance sheet after repaying its final bond in May 2026, enhancing financial flexibility amid sector volatility.
Outlook remains positive with analyst consensus at 62.5% buy ratings, supported by robust operational execution and 80% fuel hedging for 2027. Key risks include rising operating costs, geopolitical tensions affecting fuel prices, and regulatory scrutiny over seating policies. The stock's valuation appears reasonable relative to earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
